https://sti571inhibitor.com/ep....isode-involving-covi
The handling of patients with advanced pancreatic disease depends on chemotherapy and poly (ADP-ribose) polymerase inhibitors for patients who carry BRCA1/2 inactivating alterations. Some variations, such as for example huge insertion/deletions (Indels), inactivating BRCA1/2 and as a consequence of clinical relevance is difficult to identify by next-generation sequencing methods. Here we report a 47-year-old patient presenting with pancreatic cancer tumors whoever tumour harbours a
Like
Comment
Share
